Hangzhou Bio-Sincerity Pharma-Tech Stock Value
Hangzhou Bio-Sincerity Pharma-Tech Company Info
EPS Growth 5Y
0,00%
Market Cap
HK$5,76 B
Long-Term Debt
HK$0,24 B
Quarterly earnings
04/23/2026
Dividend
HK$0,00
Dividend Yield
0,00%
Founded
2011
Industry
Country
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
There are currently no price targets available for this stock.
In the last five quarters, Hangzhou Bio-Sincerity Pharma-Tech’s Price Target has risen from HK$83,82 to HK$83,82 - a 0,00% increase.
Top growth stocks in the health care sector (5Y.)
What does Hangzhou Bio-Sincerity Pharma-Tech do?
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China.
Business Segments
The company operates through Generic Drug Research and Development, Innovative Drug Research and Development, and Contract Research Organization (CRO) services.
Generic Drug Research and Development
This segment has accumulated rich experience in the research and development of generic drugs, and has established a complete technical sys...
Hangzhou Bio-Sincerity Pharma-Tech Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Industry Sales:**
- **Pharmaceutical Products:** 65%
- **Biotechnology:** 25%
- **Medical Devices:** 10%
**TOP 3 Markets:**
- **China:** 50%
- **USA:** 30%
- **Europe:** 15%
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. generates the majority of its sales from the sale of pharmaceutical products,...
At which locations are the company’s products manufactured?
**Production Site:** Hangzhou, China
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. mainly produces its pharmaceutical products in Hangzhou, China. The city is known for its advanced infrastructure and its role as a center for biotechnology and pharmacy in the region. The company benefits from its pr...
What strategy does Hangzhou Bio-Sincerity Pharma-Tech pursue for future growth?
**Revenue Growth:** Estimated 18% (2025)
**Research and Development Investments:** 25% of revenue (2025)
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. pursues a growth strategy that is heavily based on innovation and research. The company invests significantly in research and development to develop...
Which raw materials are imported and from which countries?
I'm sorry, but I do not have specific information about the commodities or materials that Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. imports, or from which countries they originate. However, companies in the pharmaceutical industry typically import raw materials such as active pharmaceutical...
How strong is the company’s competitive advantage?
**Market Share:** Estimated at 5% in 2026
**Research and Development Ratio:** 12% of revenue (2025)
**Patent Portfolio:** Over 50 active patents (2026)
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. has gained a competitive advantage through its strong focus on research and development. With an R...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** 35% (estimated, 2026)
**Insider Buys/Sells:** No significant changes (estimated, 2026)
The institutional investor share in Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. is estimated to be around 35%. This estimate is based on typical shares in the industry for com...
What percentage market share does Hangzhou Bio-Sincerity Pharma-Tech have?
**Market share of Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd.:** 3.8% (2026, estimated)
**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 12.5%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 10.2%
3. **China National Pharmaceutical Group Corporation (CNPGC):** 9.8%...
Is Hangzhou Bio-Sincerity Pharma-Tech stock currently a good investment?
**Revenue Growth:** 18% (2025)
**Research and Development Ratio:** 12% of revenue (2025)
**Market Share in China:** 5% (2025)
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. recorded a revenue growth of 18% in 2025, attributed to a strong product pipeline and successful market launches. The high resea...
Does Hangzhou Bio-Sincerity Pharma-Tech pay a dividend – and how reliable is the payout?
**Dividend payment:** No dividend (2026)
Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. did not distribute any dividends in 2026. The company has focused on reinvesting profits into growth and the development of new products in the past, rather than paying dividends to shareholders.
The reliability...
